Axsome Therapeutics (AXSM) EBITDA (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of EBITDA data on file, last reported at -$63.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 11.19% year-over-year to -$63.4 million; the trailing twelve-month figure through Mar 2026 stood at -$173.1 million (up 35.94% YoY), and the FY2025 full-year result was -$166.8 million, up 40.56% from the prior year.
• EBITDA retreated to -$63.4 million in Q1 2026, from -$27.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$6.4 million in Q1 2023 to a low of -$98.3 million in Q4 2023.
• A 5-year average of -$54.3 million and a median of -$59.9 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA soared 83.35% in 2023 and sank 955.46% in 2024, its largest moves.
• Tracing AXSM's EBITDA over 5 years: stood at -$59.9 million in 2022, then sank by 64.01% to -$98.3 million in 2023, then gained by 26.11% to -$72.6 million in 2024, then soared by 62.88% to -$27.0 million in 2025, then tumbled by 135.03% to -$63.4 million in 2026.
• Business Quant data shows AXSM's EBITDA at -$63.4 million in Q1 2026, -$27.0 million in Q4 2025, and -$46.1 million in Q3 2025.